Q1 2025 EPS Estimates for AstraZeneca PLC (NASDAQ:AZN) Lifted by Analyst

AstraZeneca PLC (NASDAQ:AZN) – Stock analysts at Zacks Research raised their Q1 2025 earnings estimates for shares of AstraZeneca in a report issued on Wednesday, October 16th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.06 per share for the quarter, up from their previous forecast of $1.05. The consensus estimate for AstraZeneca’s current full-year earnings is $4.07 per share. Zacks Research also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.18 EPS, Q4 2025 earnings at $1.23 EPS, FY2025 earnings at $4.57 EPS, Q1 2026 earnings at $1.19 EPS, Q2 2026 earnings at $1.25 EPS, Q3 2026 earnings at $1.32 EPS and FY2026 earnings at $5.12 EPS.

A number of other analysts have also commented on AZN. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen upped their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $78.31 on Thursday. The firm has a market capitalization of $242.81 billion, a PE ratio of 37.83, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46. The firm has a fifty day simple moving average of $81.26 and a two-hundred day simple moving average of $78.04. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. AstraZeneca’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.08 EPS.

Hedge Funds Weigh In On AstraZeneca

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca during the second quarter valued at about $26,000. Pathway Financial Advisers LLC purchased a new stake in AstraZeneca during the first quarter valued at about $29,000. RFP Financial Group LLC lifted its holdings in AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the last quarter. Finally, Hobbs Group Advisors LLC purchased a new stake in AstraZeneca during the second quarter valued at about $35,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Cuts Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were issued a $0.49 dividend. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend was Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is currently 47.34%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.